GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

Main Article Content

Angela Stoddart
Megan E. McNerney
Elizabeth Bartom
Rachel Bergerson
David J. Young
Zhijian Qian
Jianghong Wang
Anthony A. Fernald
Elizabeth M. Davis
Richard A. Larson
Kevin P. White
Michelle M. Le Beau *
(*) Corresponding Author:
Michelle M. Le Beau | mlebeau@medicne.bsd.uchicago.edu

Abstract

Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy.  t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.  The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective.  Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete.  Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biography

Michelle M. Le Beau, University of Chicago

  Department of MedicineProfessor